Graft-Versus-Host Disease

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

How I Treat a Patient With Triple-Relapsed Chronic Graft-Versus-Host Disease

05/08/2025

Shernan Holtan, MD

Shernan Holtan, MD, Roswell Park Comprehensive Cancer Center, outlines a treatment plan for a patient with triple-relapsed chronic graft-versus-host disease.

Shernan Holtan, MD, Roswell Park...

05/08/2025

Oncology

Alina Markova, MD, Memorial Sloan Kettering

Conference Coverage

Topical Ruxolitinib Shows Promise for Treatment of Patients With Chronic Cutaneous GVHD

01/11/2024

Alina Markova, MD

At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...

At the 65th ASH Annual Meeting...

01/11/2024

Oncology

Shernan G Holtan, MD, University of Minnesota

Conference Coverage

Selective Oral AURKA Inhibitor for Graft-Versus-Host Disease and Relapse Prophylaxis Following Allogeneic HCT

12/21/2023

Shernan Holtan, MD

At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...

At the 2023 ASH Annual Meeting,...

12/21/2023

Oncology

Daniel Wolff, MD, University Hospital Regensburg

Conference Coverage

AGAVE-201 Trial Finds Axatilimab Yields Durable Responses for R/R Chronic GVHD Treatment

12/18/2023

Daniel Wolff, MD

At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...

At the 2023 ASH Annual Meeting...

12/18/2023

Oncology

Videos

Latest Updates in Graft-Versus-Host Disease Prophylaxis

11/13/2023

Shernan Holtan, MD

Shernan Holtan, MD, explores the most recent data in terms of graft-versus-host-disease prophylaxis.

Shernan Holtan, MD, explores the...

11/13/2023

Oncology

Videos

Frontline Treatment Options for Acute Graft-Versus-Host Disease

11/13/2023

Shernan Holtan, MD

Shernan Holtan, MD, explores advances and unmet needs in the frontline treatment of patients with acute graft-versus-host-disease.

Shernan Holtan, MD, explores...

11/13/2023

Oncology

Videos

Exploring Mechanisms and Approaches for Graft-Versus-Host Disease Prophylaxis

09/05/2023

Ernst Holler, MD

Ernst Holler, MD, provides insights and analyses regarding the latest mechanisms and approaches for graft-versus-host disease prophylaxis, explaining the latest evolution of T-cell interaction methods.

Ernst Holler, MD, provides...

09/05/2023

Oncology

Videos

Analyzing Risk Factors for Acute and Chronic Graft-Versus-Host Disease

09/05/2023

Ernst Holler, MD

Ernst Holler, MD, provides expert insights into the latest data on risk factors for the development of acute and chronic graft-versus-host disease.

Ernst Holler, MD, provides...

09/05/2023

Oncology

Videos

Outcomes of Patients Treated With Abatacept for the Prevention of GVHD

08/22/2023

Benjamin Watkins, MD

Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.

Benjamin Watkins, MD, provides...

08/22/2023

Oncology

Videos

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

08/22/2023

Benjamin Watkins, MD

Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.

Benjamin Watkins, MD, discusses...

08/22/2023

Oncology

Recent News

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

News

ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD

05/10/2021

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.

Belumosudil produces high...

05/10/2021

Oncology

News

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

06/23/2020

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

In a phase 2 clinical trial,...

06/23/2020

Oncology

News

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

05/13/2020

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Ruxolitinib significantly...

05/13/2020

Oncology

FDA Approval

FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma

11/06/2026

Stephanie Holland

Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...

Results from the phase 1b/2...

11/06/2026

Oncology

News

Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit

11/05/2026

Emily Estrada

Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...

Based on results from the phase...

11/05/2026

Oncology

News

Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma

11/05/2026

Emily Estrada

Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...

Following FDA approval supported...

11/05/2026

Oncology

News

Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status

11/04/2026

Emily Estrada

Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...

Results from two phase 2 trials...

11/04/2026

Oncology

News

SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer

11/04/2026

Emily Estrada

Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...

Updated phase 1 results...

11/04/2026

Oncology

News

Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer

11/04/2026

Emily Estrada

Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...

Updated results from a phase 1...

11/04/2026

Oncology

News

Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors

11/04/2026

Emily Estrada

Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...

Results from RINGSIDE trial...

11/04/2026

Oncology

FDA Alerts

Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results

11/04/2026

Stephanie Holland

Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...

Results from the phase 3...

11/04/2026

Oncology

News

Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance

11/03/2026

Stephanie Holland

Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...

Medicare coverage has been...

11/03/2026

Oncology

News

What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium

11/02/2026

Janelle Bradley

The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.

The 2026 NANETS...

11/02/2026

Oncology